% | $
Quotes you view appear here for quick access.

Pixelworks, Inc. Message Board

powertraderpro 5 posts  |  Last Activity: Jun 16, 2016 4:22 PM Member since: Aug 25, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to


    by biogal022 Jun 16, 2016 4:15 PM
    powertraderpro powertraderpro Jun 16, 2016 4:22 PM Flag

    good to see some action somewhere. will play NEWLF and FREEF tomorrow. you can make a killing in penny land or loss a ton, but like this trade.

  • powertraderpro by powertraderpro Jun 16, 2016 4:18 PM Flag

    FREEF is still below the .43. Easy money ......NEWLF next imo

  • powertraderpro powertraderpro Jun 7, 2016 10:12 PM Flag

    CELG will out bid BMY. 25++

  • Reply to

    Best data from ASCO

    by powertraderpro Jun 7, 2016 9:58 PM
    powertraderpro powertraderpro Jun 7, 2016 10:06 PM Flag

    At the ASCO Conference on Monday, Vascular Biogenics Ltd
    VBLT 10.95%
    reported the updated response rate and mOS results for the ongoing Phase I/II trials of VB-111 in platinum-resistant ovarian cancer.

    Piper Jaffray’s Charles C. Duncan reiterated an Overweight rating on the company, with a price target of $14.

    The data presented by Vascular Biogenics showed a 60 percent response rate through CA-125 biomarker reduction.

    Related Link: Vascular Biogenics Surges 80% Off Double Catalyst

    Duncan mentioned this strengthens confidence in the platform and “VB-111’s potential to demonstrate efficacy in a second, challenging indication in addition to GBM.”

    In the high dose arm, subjects with ovarian cancer achieved a significant mOS over those on low dose.

    With regard to safety, VB-111 was “well tolerated,” with no DLTs being reported, although they “observed possibly drug related SAEs, which are to-date unconfirmed.”

    “On these results, VBLT traded higher, but our KOL diligence points to investigator interest in the differentiated MOA and hypothesis generating data,” Duncan stated.

    The analyst expects a favorable outcome around the imminent EPO2 meeting for ovarian cancer with the FDA, expected in 3Q16, while rGBM Phase 3 enrollment updates offer platform visibility in 2H16.

  • powertraderpro by powertraderpro Jun 7, 2016 9:58 PM Flag

    VBLT may be the best. If not a close second. Will soon be a 12+ stock. Big pharma is running out of drugs. They will likely try to takeover this company as they have phase 2/3 trials that look very promising.

3.16-0.07(-2.17%)12:20 PMEDT